OverviewLung cancer is the leading cause of cancer-related death in the United States. An estimated 219,440 new cases (116,090 men; 103,350 women) of lung and bronchus cancer were diagnosed in 2009, and 159,390 deaths (88,900 men; 70,490 women) occurred from the disease.1 Only 15% of all lung cancer patients are alive 5 years or more after diagnosis (http://seer.cancer.gov/statfacts/html/lungb.html). Common symptoms of lung cancer include cough, dyspnea, weight loss, and chest pain; symptomatic patients are more likely to have chronic obstructive pulmonary disease.The primary risk factor for lung cancer is smoking, which accounts for more than 85% of all lung cancer-related deaths.2 The risk for lung cancer increases with the number of cigarettes smoked per day and the number of years spent smoking. In addition to the hazard of first-hand smoke, exposed nonsmokers have an increased relative risk for developing lung cancer.3 Radon gas, a radioactive gas that is produced by the decay of radium 226, is the second leading cause of lung cancer.4 The decay of this isotope leads to the production of substances that emit alpha-particles, which may cause cell damage and therefore increase the potential for malignant transformation. Data suggest that postmenopausal women who smoke or are former smokers should not undergo hormone replacement therapy, because it increases the risk for death from non–small cell lung cancer (NSCLC).5Asbestos, a mineral compound that breaks into small airborne shards, is a known carcinogen that increases the risk for lung cancer in people exposed to the airborne fibers,...
ChlebowskiRTSchwartzAGWakeleeH. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet2009;374:1243–1251.
ChlebowskiRTSchwartzAGWakeleeH. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet2009;374:1243–1251.
)| false
JorenbyDEHaysJTRigottiNA. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA2006;296:56–63.
JorenbyDEHaysJTRigottiNA. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA2006;296:56–63.
)| false
GonzalesDRennardSINidesM. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA2006;296:47–55.
GonzalesDRennardSINidesM. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA2006;296:47–55.
)| false
ChuteJPChenTFeigalE. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol1999;17:1794–1801.
ChuteJPChenTFeigalE. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol1999;17:1794–1801.
)| false
HenschkeCIMcCauleyDIYankelevitzDF. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet1999;354:99–105.
HenschkeCIMcCauleyDIYankelevitzDF. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet1999;354:99–105.
)| false
McMahonPMKongCYJohnsonBE. Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology2008;248:278–287.
McMahonPMKongCYJohnsonBE. Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology2008;248:278–287.
)| false
vanKlaveren RVOudkerkMMaliW. Baseline and second round results from the population based Dutch-Belgian randomized lung cancer screening trial (NELSON) [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 1508.
vanKlaveren RVOudkerkMMaliW. Baseline and second round results from the population based Dutch-Belgian randomized lung cancer screening trial (NELSON) [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 1508.
)| false
VeeramachaneniNKCrabtreeTDKreiselD. A thoracic surgery clinic dedicated to indeterminate pulmonary nodules: too many scans and too little pathology?J Thorac Cardiovasc Surg2009;137:30–35.
VeeramachaneniNKCrabtreeTDKreiselD. A thoracic surgery clinic dedicated to indeterminate pulmonary nodules: too many scans and too little pathology?J Thorac Cardiovasc Surg2009;137:30–35.
)| false
HorioYTakahashiTKuroishiT. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res1993;53:1–4.
HorioYTakahashiTKuroishiT. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res1993;53:1–4.
)| false
EberhardDAJohnsonBEAmlerLC. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol2005;23:5900–5909.
EberhardDAJohnsonBEAmlerLC. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol2005;23:5900–5909.
)| false
CappuzzoFLigorioCToschiL. EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol2007;2:423–429.
CappuzzoFLigorioCToschiL. EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol2007;2:423–429.
)| false
TravisWDBrambillaEMüller-HermelinkHKHarrisCC. Pathology and Genetics of Tumours of the Lung Pleura Thymus and Heart. Lyon: IARC Press; 2004.
TravisWDBrambillaEMüller-HermelinkHKHarrisCC. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004.
)| false
JackmanDMChirieacLRJannePA. Bronchioloalveolar carcinoma: a review of the epidemiology, pathology, and treatment. Semin Respir Crit Care Med2005;26:342–352.
JackmanDMChirieacLRJannePA. Bronchioloalveolar carcinoma: a review of the epidemiology, pathology, and treatment. Semin Respir Crit Care Med2005;26:342–352.
)| false
BlonsHCoteJFLe CorreD. Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation. Am J Surg Pathol2006;30:1309–1315.
BlonsHCoteJFLe CorreD. Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation. Am J Surg Pathol2006;30:1309–1315.
)| false
WestHLFranklinWAMcCoyJ. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group study S0126. J Clin Oncol2006;24:1807–1813.
WestHLFranklinWAMcCoyJ. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group study S0126. J Clin Oncol2006;24:1807–1813.
)| false
GoldsteinNSThomasM. Mucinous and nonmucinous bronchioloalveolar adenocarcinomas have distinct staining patterns with thyroid transcription factor and cytokeratin 20 antibodies. Am J Clin Pathol2001;116:319–325.
GoldsteinNSThomasM. Mucinous and nonmucinous bronchioloalveolar adenocarcinomas have distinct staining patterns with thyroid transcription factor and cytokeratin 20 antibodies. Am J Clin Pathol2001;116:319–325.
)| false
OrdonezNG. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol2005;36:372–380.
OrdonezNG. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol2005;36:372–380.
)| false
GuineeDG JrFishbackNFKossMN. The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies. Am J Clin Pathol1994;102:406–414.
GuineeDG JrFishbackNFKossMN. The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies. Am J Clin Pathol1994;102:406–414.
)| false
GoldstrawPCrowleyJChanskyK. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol2007;2:706–714.
GoldstrawPCrowleyJChanskyK. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol2007;2:706–714.
)| false
OuSHZellJAZiogasAAnton-CulverH. Prognostic factors for survival of stage I nonsmall cell lung cancer patients: a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003. Cancer2007;110:1532–1541.
OuSHZellJAZiogasAAnton-CulverH. Prognostic factors for survival of stage I nonsmall cell lung cancer patients: a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003. Cancer2007;110:1532–1541.
)| false
SimonGRSharmaSCantorA. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest2005;127:978–983.
SimonGRSharmaSCantorA. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest2005;127:978–983.
)| false
OlaussenKADunantAFouretP. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med2006;355:983–991.
OlaussenKADunantAFouretP. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med2006;355:983–991.
)| false
BeplerGKusmartsevaISharmaS. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in nonsmall-cell lung cancer. J Clin Oncol2006;24:4731–4737.
BeplerGKusmartsevaISharmaS. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in nonsmall-cell lung cancer. J Clin Oncol2006;24:4731–4737.
)| false
TsaoMSAviel-RonenSDingK. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol2007;25:5240–5247.
TsaoMSAviel-RonenSDingK. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol2007;25:5240–5247.
)| false
BeplerGSharmaSCantorA. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol2004;22:1878–1885.
BeplerGSharmaSCantorA. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol2004;22:1878–1885.
)| false
BeplerGLiXSchellM. Predictive value of RRM1 and ERCC1 protein levels in a prospective community-based trial of gemcitabine/carboplatin (GC) vs gemcitabine (G) alone [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 8033.
BeplerGLiXSchellM. Predictive value of RRM1 and ERCC1 protein levels in a prospective community-based trial of gemcitabine/carboplatin (GC) vs gemcitabine (G) alone [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 8033.
)| false
ReynoldsCObasajuCSchellMJ. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol2009;27:5808–5815.
ReynoldsCObasajuCSchellMJ. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol2009;27:5808–5815.
)| false
LynchTJBellDWSordellaR. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med2004;350:2129–2139.
LynchTJBellDWSordellaR. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med2004;350:2129–2139.
)| false
LordRVBrabenderJGandaraD. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res2002;8:2286–2291.
LordRVBrabenderJGandaraD. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res2002;8:2286–2291.
)| false
RodenhuisSvan de WeteringMLMooiWJ. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med1987;317:929–935.
RodenhuisSvan de WeteringMLMooiWJ. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med1987;317:929–935.
)| false
SlebosRJHrubanRHDalesioO. Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst1991;83:1024–1027.
SlebosRJHrubanRHDalesioO. Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst1991;83:1024–1027.
)| false
MitsudomiTSteinbergSMOieHK. Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res1991;51:4999–5002.
MitsudomiTSteinbergSMOieHK. Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res1991;51:4999–5002.
)| false
BrissendenJECarasIThelanderLFranckeU. The structural gene for the M1 subunit of ribonucleotide reductase maps to chromosome 11, band p15, in human and to chromosome 7 in mouse. Exp Cell Res1988;174:302–308.
BrissendenJECarasIThelanderLFranckeU. The structural gene for the M1 subunit of ribonucleotide reductase maps to chromosome 11, band p15, in human and to chromosome 7 in mouse. Exp Cell Res1988;174:302–308.
)| false
RosellRDanenbergKDAlberolaV. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res2004;10:1318–1325.
RosellRDanenbergKDAlberolaV. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res2004;10:1318–1325.
)| false
BoffaDJAllenMSGrabJD. Data from The Society of Thoracic Surgeons General Thoracic Surgery database: the surgical management of primary lung tumors. J Thorac Cardiovasc Surg2008;135:247–254.
BoffaDJAllenMSGrabJD. Data from The Society of Thoracic Surgeons General Thoracic Surgery database: the surgical management of primary lung tumors. J Thorac Cardiovasc Surg2008;135:247–254.
)| false
ScottWJHowingtonJFeigenbergS. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest2007;132:234S–242S.
ScottWJHowingtonJFeigenbergS. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest2007;132:234S–242S.
)| false
GinsbergRJRubinsteinLV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg1995;60:615–622; discussion 622–613.
GinsbergRJRubinsteinLV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg1995;60:615–622; discussion 622–613.
)| false
AllenMSDarlingGEPechetTT. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg2006;81:1013–1019; discussion 1019–1020.
AllenMSDarlingGEPechetTT. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg2006;81:1013–1019; discussion 1019–1020.
)| false
AllenMSDarlingGEDeckerPA. Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective ACOSOG Z0030 trial [abstract]. J Clin Oncol2007;25(Suppl):Abstract 7555.
AllenMSDarlingGEDeckerPA. Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective ACOSOG Z0030 trial [abstract]. J Clin Oncol2007;25(Suppl):Abstract 7555.
)| false
RuschVWAsamuraHWatanabeH. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol2009;4:568–577.
RuschVWAsamuraHWatanabeH. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol2009;4:568–577.
)| false
SienelWDangoSKirschbaumA. Sublobar resections in stage IA non-small cell lung cancer: segmentectomies result in significantly better cancer-related survival than wedge resections. Eur J Cardiothorac Surg2008;33:728–734.
SienelWDangoSKirschbaumA. Sublobar resections in stage IA non-small cell lung cancer: segmentectomies result in significantly better cancer-related survival than wedge resections. Eur J Cardiothorac Surg2008;33:728–734.
)| false
SienelWStremmelCKirschbaumA. Frequency of local recurrence following segmentectomy of stage IA non-small cell lung cancer is influenced by segment localisation and width of resection margins—implications for patient selection for segmentectomy. Eur J Cardiothorac Surg2007;31:522–527; discussion 527–528.
SienelWStremmelCKirschbaumA. Frequency of local recurrence following segmentectomy of stage IA non-small cell lung cancer is influenced by segment localisation and width of resection margins—implications for patient selection for segmentectomy. Eur J Cardiothorac Surg2007;31:522–527; discussion 527–528.
)| false
ShawJPDembitzerFRWisniveskyJP. Video-assisted thoracoscopic lobectomy: state of the art and future directions. Ann Thorac Surg2008;85:S705–709.
ShawJPDembitzerFRWisniveskyJP. Video-assisted thoracoscopic lobectomy: state of the art and future directions. Ann Thorac Surg2008;85:S705–709.
)| false
ChengDDowneyRJKernstineK. Video-assisted thoracic surgery in lung cancer resection: a meta-analysis and systematic review of controlled trials. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery2007;2:261–292.
ChengDDowneyRJKernstineK. Video-assisted thoracic surgery in lung cancer resection: a meta-analysis and systematic review of controlled trials. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery2007;2:261–292.
)| false
WhitsonBAAndradeRSBoettcherA. Video-assisted thoracoscopic surgery is more favorable than thoracotomy for resection of clinical stage I non-small cell lung cancer. Ann Thorac Surg2007;83:1965–1970.
WhitsonBAAndradeRSBoettcherA. Video-assisted thoracoscopic surgery is more favorable than thoracotomy for resection of clinical stage I non-small cell lung cancer. Ann Thorac Surg2007;83:1965–1970.
)| false
WhitsonBAGrothSSDuvalSJ. Surgery for early-stage non-small cell lung cancer: a systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy. Ann Thorac Surg2008;86:2008–2016; discussion 2016–2018.
WhitsonBAGrothSSDuvalSJ. Surgery for early-stage non-small cell lung cancer: a systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy. Ann Thorac Surg2008;86:2008–2016; discussion 2016–2018.
)| false
AtkinsBZHarpoleDHJrMangumJH. Pulmonary segmentectomy by thoracotomy or thoracoscopy: reduced hospital length of stay with a minimally-invasive approach. Ann Thorac Surg2007;84:1107–1112; discussion 1112–1113.
AtkinsBZHarpoleDHJrMangumJH. Pulmonary segmentectomy by thoracotomy or thoracoscopy: reduced hospital length of stay with a minimally-invasive approach. Ann Thorac Surg2007;84:1107–1112; discussion 1112–1113.
)| false
OhtsukaTNomoriHHorioH. Is major pulmonary resection by video-assisted thoracic surgery an adequate procedure in clinical stage I lung cancer?Chest2004;125:1742–1746.
OhtsukaTNomoriHHorioH. Is major pulmonary resection by video-assisted thoracic surgery an adequate procedure in clinical stage I lung cancer?Chest2004;125:1742–1746.
)| false
CattaneoSMParkBJWiltonAS. Use of video-assisted thoracic surgery for lobectomy in the elderly results in fewer complications. Ann Thorac Surg2008;85:231–235; discussion 235–236.
CattaneoSMParkBJWiltonAS. Use of video-assisted thoracic surgery for lobectomy in the elderly results in fewer complications. Ann Thorac Surg2008;85:231–235; discussion 235–236.
)| false
ThomasPDoddoliCYenaS. VATS is an adequate oncological operation for stage I non-small cell lung cancer. Eur J Cardiothorac Surg2002;21:1094–1099.
ThomasPDoddoliCYenaS. VATS is an adequate oncological operation for stage I non-small cell lung cancer. Eur J Cardiothorac Surg2002;21:1094–1099.
)| false
SolainiLPruscianoFBagioniPPoddieDB. Long-term results of video-assisted thoracic surgery lobectomy for stage I non-small cell lung cancer: a single-centre study of 104 cases. Interact Cardiovasc Thorac Surg2004;3:57–62.
SolainiLPruscianoFBagioniPPoddieDB. Long-term results of video-assisted thoracic surgery lobectomy for stage I non-small cell lung cancer: a single-centre study of 104 cases. Interact Cardiovasc Thorac Surg2004;3:57–62.
)| false
PetersenRPPhamDBurfeindWR. Thoracoscopic lobectomy facilitates the delivery of chemotherapy after resection for lung cancer. Ann Thorac Surg2007;83:1245–1249.
PetersenRPPhamDBurfeindWR. Thoracoscopic lobectomy facilitates the delivery of chemotherapy after resection for lung cancer. Ann Thorac Surg2007;83:1245–1249.
)| false
Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. The Lung Cancer Study Group. N Engl J Med1986;315:1377–1381.
Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. The Lung Cancer Study Group. N Engl J Med1986;315:1377–1381.
)| false
KellerSMAdakSWagnerH. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med2000;343:1217–1222.
KellerSMAdakSWagnerH. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med2000;343:1217–1222.
)| false
DouillardJYRosellRDe LenaM. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys2008;72:695–701.
DouillardJYRosellRDe LenaM. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys2008;72:695–701.
)| false
BradleyJDPaulusRGrahamMV. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group–RTOG 9705. J Clin Oncol2005;23:3480–3487.
BradleyJDPaulusRGrahamMV. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group–RTOG 9705. J Clin Oncol2005;23:3480–3487.
)| false
FeigenbergSJHanlonALLangerC. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer. J Thorac Oncol2007;2:287–292.
FeigenbergSJHanlonALLangerC. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer. J Thorac Oncol2007;2:287–292.
)| false
AlbainKSRuschVWCrowleyJJ. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol1995;13:1880–1892.
AlbainKSRuschVWCrowleyJJ. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol1995;13:1880–1892.
)| false
AlbainKSSwannRSRuschVR. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309) [abstract]. J Clin Oncol2005;23(Suppl 1):Abstract 7014.
AlbainKSSwannRSRuschVR. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309) [abstract]. J Clin Oncol2005;23(Suppl 1):Abstract 7014.
)| false
CerfolioRJBryantASJonesVLCerfolioRM. Pulmonary resection after concurrent chemotherapy and high dose (60Gy) radiation for non-small cell lung cancer is safe and may provide increased survival. Eur J Cardiothorac Surg2009;35:718–723.
CerfolioRJBryantASJonesVLCerfolioRM. Pulmonary resection after concurrent chemotherapy and high dose (60Gy) radiation for non-small cell lung cancer is safe and may provide increased survival. Eur J Cardiothorac Surg2009;35:718–723.
)| false
KwongKFEdelmanMJSuntharalingamM. High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival. J Thorac Cardiovasc Surg2005;129:1250–1257.
KwongKFEdelmanMJSuntharalingamM. High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival. J Thorac Cardiovasc Surg2005;129:1250–1257.
)| false
BradleyJGrahamMVWinterK. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys2005;61:318–328.
BradleyJGrahamMVWinterK. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys2005;61:318–328.
)| false
KongFMTen HakenRKSchipperMJ. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys2005;63:324–333.
KongFMTen HakenRKSchipperMJ. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys2005;63:324–333.
)| false
ZhaoLWestBTHaymanJA. High radiation dose may reduce the negative effect of large gross tumor volume in patients with medically inoperable early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys2007;68:103–110.
ZhaoLWestBTHaymanJA. High radiation dose may reduce the negative effect of large gross tumor volume in patients with medically inoperable early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys2007;68:103–110.
)| false
WangLCorreaCRZhaoL. The effect of radiation dose and chemotherapy on overall survival in 237 patients with stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys2009;73:1383–1390.
WangLCorreaCRZhaoL. The effect of radiation dose and chemotherapy on overall survival in 237 patients with stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys2009;73:1383–1390.
)| false
SchildSEMcGinnisWLGrahamD. Results of a phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys2006;65:1106–1111.
SchildSEMcGinnisWLGrahamD. Results of a phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys2006;65:1106–1111.
)| false
BradleyJDGrahamMSuzanneS. Phase I results of RTOG L-0117; a phase I/II dose intensification study using 3DCRT and concurrent chemotherapy for patients with inoperable NSCLC [abstract]. J Clin Oncol2005;23(Suppl 1):Abstract 7063.
BradleyJDGrahamMSuzanneS. Phase I results of RTOG L-0117; a phase I/II dose intensification study using 3DCRT and concurrent chemotherapy for patients with inoperable NSCLC [abstract]. J Clin Oncol2005;23(Suppl 1):Abstract 7063.
)| false
KelseyCRLightKLMarksLB. Patterns of failure after resection of non-small-cell lung cancer: implications for postoperative radiation therapy volumes. Int J Radiat Oncol Biol Phys2006;65:1097–1105.
KelseyCRLightKLMarksLB. Patterns of failure after resection of non-small-cell lung cancer: implications for postoperative radiation therapy volumes. Int J Radiat Oncol Biol Phys2006;65:1097–1105.
)| false
BelderbosJSKepkaLSpring KongFM. Report from the International Atomic Energy Agency (IAEA) consultants' meeting on elective nodal irradiation in lung cancer: non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys2008;72:335–342.
BelderbosJSKepkaLSpring KongFM. Report from the International Atomic Energy Agency (IAEA) consultants' meeting on elective nodal irradiation in lung cancer: non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys2008;72:335–342.
)| false
YuanSSunXLiM. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. Am J Clin Oncol2007;30:239–244.
YuanSSunXLiM. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. Am J Clin Oncol2007;30:239–244.
)| false
Sanuki-FujimotoNSumiMItoY. Relation between elective nodal failure and irradiated volume in non-small-cell lung cancer (NSCLC) treated with radiotherapy using conventional fields and doses. Radiother Oncol2009;91:433–437.
Sanuki-FujimotoNSumiMItoY. Relation between elective nodal failure and irradiated volume in non-small-cell lung cancer (NSCLC) treated with radiotherapy using conventional fields and doses. Radiother Oncol2009;91:433–437.
)| false
SulmanEPKomakiRKloppAH. Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer. Radiat Oncol2009;4:5.
SulmanEPKomakiRKloppAH. Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer. Radiat Oncol2009;4:5.
)| false
GrahamMVPurdyJAEmamiB. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys1999;45:323–329.
GrahamMVPurdyJAEmamiB. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys1999;45:323–329.
)| false
KongFMHaymanJAGriffithKA. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys2006;65:1075–1086.
KongFMHaymanJAGriffithKA. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys2006;65:1075–1086.
)| false
HernandoMLMarksLBBentelGC. Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys2001;51:650–659.
HernandoMLMarksLBBentelGC. Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys2001;51:650–659.
)| false
KimTHChoKHPyoHR. Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer. Radiology2005;235:208–215.
KimTHChoKHPyoHR. Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer. Radiology2005;235:208–215.
)| false
WangSLiaoZWeiX. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys2006;66:1399–1407.
WangSLiaoZWeiX. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys2006;66:1399–1407.
)| false
RoseJRodriguesGYaremkoB. Systematic review of dose-volume parameters in the prediction of esophagitis in thoracic radiotherapy. Radiother Oncol2009;91:282–287.
RoseJRodriguesGYaremkoB. Systematic review of dose-volume parameters in the prediction of esophagitis in thoracic radiotherapy. Radiother Oncol2009;91:282–287.
)| false
HallWHGuiouMLeeNY. Development and validation of a standardized method for contouring the brachial plexus: preliminary dosimetric analysis among patients treated with IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys2008;72:1362–1367.
HallWHGuiouMLeeNY. Development and validation of a standardized method for contouring the brachial plexus: preliminary dosimetric analysis among patients treated with IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys2008;72:1362–1367.
)| false
MacManusMNestleURosenzweigKE. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006–2007. Radiother Oncol2009;91:85–94.
MacManusMNestleURosenzweigKE. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006–2007. Radiother Oncol2009;91:85–94.
)| false
LiaoZXKomakiRRThamesHDJr. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys2010;76:775–781.
LiaoZXKomakiRRThamesHDJr. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys2010;76:775–781.
)| false
ChangJYZhangXWangX. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in stage I or stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys2006;65:1087–1096.
ChangJYZhangXWangX. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in stage I or stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys2006;65:1087–1096.
)| false
GruttersJPKesselsAGPijls-JohannesmaM. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother Oncol2010;95:32–40.
GruttersJPKesselsAGPijls-JohannesmaM. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother Oncol2010;95:32–40.
)| false
OnishiHArakiTShiratoH. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multi-institutional study. Cancer2004;101:1623–1631.
OnishiHArakiTShiratoH. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multi-institutional study. Cancer2004;101:1623–1631.
)| false
TimmermanRMcGarryRYiannoutsosC. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol2006;24:4833–4839.
TimmermanRMcGarryRYiannoutsosC. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol2006;24:4833–4839.
)| false
LagerwaardFJHaasbeekCJSmitEF. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys2008;70:685–692.
LagerwaardFJHaasbeekCJSmitEF. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys2008;70:685–692.
)| false
FakirisAJMcGarryRCYiannoutsosCT. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys2009;75:677–682.
FakirisAJMcGarryRCYiannoutsosCT. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys2009;75:677–682.
)| false
BaumannPNymanJHoyerM. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol2009;27:3290–3296.
BaumannPNymanJHoyerM. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol2009;27:3290–3296.
)| false
GuckenbergerMWulfJMuellerG. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys2009;74:47–54.
GuckenbergerMWulfJMuellerG. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys2009;74:47–54.
)| false
ChangELWefelJSHessKR. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol2009;10:1037–1044.
ChangELWefelJSHessKR. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol2009;10:1037–1044.
)| false
RadesDKueterJDHornungD. Comparison of stereotactic radiosurgery (SRS) alone and whole brain radiotherapy (WBRT) plus a stereotactic boost (WBRT+SRS) for one to three brain metastases. Strahlenther Onkol2008;184:655–662.
RadesDKueterJDHornungD. Comparison of stereotactic radiosurgery (SRS) alone and whole brain radiotherapy (WBRT) plus a stereotactic boost (WBRT+SRS) for one to three brain metastases. Strahlenther Onkol2008;184:655–662.
)| false
AoyamaHShiratoHTagoM. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA2006;295:2483–2491.
AoyamaHShiratoHTagoM. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA2006;295:2483–2491.
)| false
MehtaMPTsaoMNWhelanTJ. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys2005;63:37–46.
MehtaMPTsaoMNWhelanTJ. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys2005;63:37–46.
)| false
ChangJYBalterPADongL. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys2008;72:967–971.
ChangJYBalterPADongL. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys2008;72:967–971.
)| false
TakedaASanukiNKuniedaE. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm. Int J Radiat Oncol Biol Phys2009;73:442–448.
TakedaASanukiNKuniedaE. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm. Int J Radiat Oncol Biol Phys2009;73:442–448.
)| false
StephansKLDjemilTReddyCA. A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience. J Thorac Oncol2009;4:976–982.
StephansKLDjemilTReddyCA. A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience. J Thorac Oncol2009;4:976–982.
)| false
JinJYKongFMChettyIJ. Impact of fraction size on lung radiation toxicity: hypofractionation may be beneficial in dose escalation of radiotherapy for lung cancers. Int J Radiat Oncol Biol Phys2010;76:782–788.
JinJYKongFMChettyIJ. Impact of fraction size on lung radiation toxicity: hypofractionation may be beneficial in dose escalation of radiotherapy for lung cancers. Int J Radiat Oncol Biol Phys2010;76:782–788.
)| false
OnishiHShiratoHNagataY. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol2007;2:S94–100.
OnishiHShiratoHNagataY. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol2007;2:S94–100.
)| false
LencioniRCrocettiLCioniR. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol2008;9:621–628.
LencioniRCrocettiLCioniR. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol2008;9:621–628.
)| false
LiJBentzenSMRenschlerMMehtaMP. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol2007;25:1260–1266.
LiJBentzenSMRenschlerMMehtaMP. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol2007;25:1260–1266.
)| false
AoyamaHTagoMKatoN. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys2007;68:1388–1395.
AoyamaHTagoMKatoN. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys2007;68:1388–1395.
)| false
GoreEMBaeKWongS. A phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer: initial analysis of Radiation Therapy Oncology Group 0214 [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract 7506.
GoreEMBaeKWongS. A phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer: initial analysis of Radiation Therapy Oncology Group 0214 [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract 7506.
)| false
LePechoux CDunantASenanS. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol2009;10:467–474.
LePechoux CDunantASenanS. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol2009;10:467–474.
)| false
WintonTLivingstonRJohnsonD. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med2005;352:2589–2597.
WintonTLivingstonRJohnsonD. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med2005;352:2589–2597.
)| false
DouillardJYRosellRDe LenaM. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol2006;7:719–727.
DouillardJYRosellRDe LenaM. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol2006;7:719–727.
)| false
FuruseKFukuokaMKawaharaM. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol1999;17:2692–2699.
FuruseKFukuokaMKawaharaM. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol1999;17:2692–2699.
)| false
AzzoliCGBakerSJrTeminS. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol2009;27:6251–6266.
AzzoliCGBakerSJrTeminS. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol2009;27:6251–6266.
)| false
NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol2008;26:4617–4625.
NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol2008;26:4617–4625.
)| false
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ1995;311:899–909.
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ1995;311:899–909.
)| false
Le ChevalierTDunantAArriagadaR. Long-term results of the International Adjuvant Lung Cancer Trial (IALT) evaluating adjuvant cisplatin-based chemotherapy in resected non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 7507.
Le ChevalierTDunantAArriagadaR. Long-term results of the International Adjuvant Lung Cancer Trial (IALT) evaluating adjuvant cisplatin-based chemotherapy in resected non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 7507.
)| false
ArriagadaRDunantAPignonJP. Long-term results of the International Adjuvant Lung Cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol2010;28:35–42.
ArriagadaRDunantAPignonJP. Long-term results of the International Adjuvant Lung Cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol2010;28:35–42.
)| false
ButtsCADingKSeymourL. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol2010;28:29–34.
ButtsCADingKSeymourL. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol2010;28:29–34.
)| false
PignonJPTribodetHScagliottiGV. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol2008;26:3552–3559.
PignonJPTribodetHScagliottiGV. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol2008;26:3552–3559.
)| false
StraussGMHerndonJMaddausMA. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633 [abstract]. J Clin Oncol2004;22(Suppl 1):Abstract 7019.
StraussGMHerndonJMaddausMA. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633 [abstract]. J Clin Oncol2004;22(Suppl 1):Abstract 7019.
)| false
StraussGMHerndonJEIIMaddausMA. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633 [abstract]. J Clin Oncol2006;24(Suppl 1):Abstract 7007.
StraussGMHerndonJEIIMaddausMA. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633 [abstract]. J Clin Oncol2006;24(Suppl 1):Abstract 7007.
)| false
StraussGMHerndonJEIIMaddausMA. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group study groups. J Clin Oncol2008;26:5043–5051.
StraussGMHerndonJEIIMaddausMA. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group study groups. J Clin Oncol2008;26:5043–5051.
)| false
OheYOhashiYKubotaK. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan. Ann Oncol2007;18:317–323.
OheYOhashiYKubotaK. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan. Ann Oncol2007;18:317–323.
)| false
DillmanROSeagrenSLPropertKJ. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med1990;323:940–945.
DillmanROSeagrenSLPropertKJ. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med1990;323:940–945.
)| false
LeChevalier TArriagadaRQuoixE. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst1991;83:417–423.
LeChevalier TArriagadaRQuoixE. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst1991;83:417–423.
)| false
SchaakeKoningCvan den BogaertWDalesioO. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med1992;326:524–530.
SchaakeKoningCvan den BogaertWDalesioO. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med1992;326:524–530.
)| false
DillmanROSeagrenSLHerndonJ. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer: five-year follow-up of cancer and leukemia group B (CALGB) 8433 trial [abstract]. J Clin Oncol1993;12:Abstract 329.
DillmanROSeagrenSLHerndonJ. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer: five-year follow-up of cancer and leukemia group B (CALGB) 8433 trial [abstract]. J Clin Oncol1993;12:Abstract 329.
)| false
DillmanROHerndonJSeagrenSL. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst1996;88:1210–1215.
DillmanROHerndonJSeagrenSL. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst1996;88:1210–1215.
)| false
BelaniCPChoyHBonomiP. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol2005;23:5883–5891.
BelaniCPChoyHBonomiP. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol2005;23:5883–5891.
)| false
VokesEEHerndonJEIICrawfordJ. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol2002;20:4191–4198.
VokesEEHerndonJEIICrawfordJ. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol2002;20:4191–4198.
)| false
GandaraDRChanskyKAlbainKS. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group study S9504. J Clin Oncol2003;21:2004–2010.
GandaraDRChanskyKAlbainKS. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group study S9504. J Clin Oncol2003;21:2004–2010.
)| false
GandaraDRChanskyKAlbainKS. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504). Clin Lung Cancer2006;8:116–121.
GandaraDRChanskyKAlbainKS. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504). Clin Lung Cancer2006;8:116–121.
)| false
HannaNHNeubauerMAnsariR. Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023 [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 7512.
HannaNHNeubauerMAnsariR. Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023 [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 7512.
)| false
MinaLANeubauerMAAnsariRH. Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023—updated results [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 7519.
MinaLANeubauerMAAnsariRH. Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023—updated results [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 7519.
)| false
HuberRMFlentjeMSchmidtM. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group. J Clin Oncol2006;24:4397–4404.
HuberRMFlentjeMSchmidtM. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group. J Clin Oncol2006;24:4397–4404.
)| false
MagilliganDJ JrDuvernoyCMalikG. Surgical approach to lung cancer with solitary cerebral metastasis: twenty-five years' experience. Ann Thorac Surg1986;42:360–364.
MagilliganDJ JrDuvernoyCMalikG. Surgical approach to lung cancer with solitary cerebral metastasis: twenty-five years' experience. Ann Thorac Surg1986;42:360–364.
)| false
FossellaFPereiraJRvon PawelJ. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol2003;21:3016–3024.
FossellaFPereiraJRvon PawelJ. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol2003;21:3016–3024.
)| false
SmitEFvan MeerbeeckJPLianesP. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group–EORTC 08975. J Clin Oncol2003;21:3909–3917.
SmitEFvan MeerbeeckJPLianesP. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group–EORTC 08975. J Clin Oncol2003;21:3909–3917.
)| false
ZatloukalPPetruzelkaLZemanovaM. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer2004;46:87–98.
ZatloukalPPetruzelkaLZemanovaM. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer2004;46:87–98.
)| false
ScagliottiGVParikhPvon PawelJ. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol2008;26:3543–3551.
ScagliottiGVParikhPvon PawelJ. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol2008;26:3543–3551.
)| false
KellyKCrowleyJBunnPAJr. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol2001;19:3210–3218.
KellyKCrowleyJBunnPAJr. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol2001;19:3210–3218.
)| false
DansonSMiddletonMRO'ByrneKJ. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer2003;98:542–553.
DansonSMiddletonMRO'ByrneKJ. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer2003;98:542–553.
)| false
BootonRLoriganPAndersonH. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol2006;17:1111–1119.
BootonRLoriganPAndersonH. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol2006;17:1111–1119.
)| false
PujolJLBretonJLGervaisR. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol2005;16:602–610.
PujolJLBretonJLGervaisR. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol2005;16:602–610.
)| false
RizviNARielyGJAzzoliCG. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Oncol2008;26:639–643.
RizviNARielyGJAzzoliCG. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Oncol2008;26:639–643.
)| false
GreenMRManikhasGMOrlovS. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol2006;17:1263–1268.
GreenMRManikhasGMOrlovS. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol2006;17:1263–1268.
)| false
SequistLVJoshiVAJannePA. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist2007;12:90–98.
SequistLVJoshiVAJannePA. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist2007;12:90–98.
)| false
InoueAKobayashiKUsuiK. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol2009;27:1394–1400.
InoueAKobayashiKUsuiK. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol2009;27:1394–1400.
)| false
PirkerRPereiraJRSzczesnaA. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet2009;373:1525–1531.
PirkerRPereiraJRSzczesnaA. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet2009;373:1525–1531.
)| false
PatelJDHensingTARademakerA. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol2009;27:3284–3289.
PatelJDHensingTARademakerA. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol2009;27:3284–3289.
)| false
CiuleanuTBrodowiczTZielinskiC. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet2009;374:1432–1440.
CiuleanuTBrodowiczTZielinskiC. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet2009;374:1432–1440.
)| false
CappuzzoFCiuleanuTStelmakhL. SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract 8001.
CappuzzoFCiuleanuTStelmakhL. SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract 8001.
)| false
PattersonGAGinsbergRJPoonPY. A prospective evaluation of magnetic resonance imaging, computed tomography, and mediastinoscopy in the preoperative assessment of mediastinal node status in bronchogenic carcinoma. J Thorac Cardiovasc Surg1987;94:679–684.
PattersonGAGinsbergRJPoonPY. A prospective evaluation of magnetic resonance imaging, computed tomography, and mediastinoscopy in the preoperative assessment of mediastinal node status in bronchogenic carcinoma. J Thorac Cardiovasc Surg1987;94:679–684.
)| false
Gonzalez-StawinskiGVLemaireAMerchantF. A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer. J Thorac Cardiovasc Surg2003;126:1900–1905.
Gonzalez-StawinskiGVLemaireAMerchantF. A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer. J Thorac Cardiovasc Surg2003;126:1900–1905.
)| false
TournoyKGMaddensSGosselinR. Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study. Thorax2007;62:696–701.
TournoyKGMaddensSGosselinR. Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study. Thorax2007;62:696–701.
)| false
MeyersBFHaddadFSiegelBA. Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer. J Thorac Cardiovasc Surg2006;131:822–829.
MeyersBFHaddadFSiegelBA. Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer. J Thorac Cardiovasc Surg2006;131:822–829.
)| false
DillemansBDeneffeGVerschakelenJDecramerM. Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small cell lung cancer. A study of 569 patients. Eur J Cardiothorac Surg1994;8:37–42.
DillemansBDeneffeGVerschakelenJDecramerM. Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small cell lung cancer. A study of 569 patients. Eur J Cardiothorac Surg1994;8:37–42.
)| false
McLoudTCBourgouinPMGreenbergRW. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology1992;182:319–323.
McLoudTCBourgouinPMGreenbergRW. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology1992;182:319–323.
)| false
ChinR JrWardRKeyesJW. Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am J Respir Crit Care Med1995;152:2090–2096.
ChinR JrWardRKeyesJW. Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am J Respir Crit Care Med1995;152:2090–2096.
)| false
KernstineKHTrappJFCroftDR. Comparison of positron emission tomography (PET) and computed tomography (CT) to identify N2 and N3 disease in non small cell lung cancer (NSCLC) [abstract]. Presented at the 1998 American Society of Clinical Oncology Meeting; Abstract 1762.
KernstineKHTrappJFCroftDR. Comparison of positron emission tomography (PET) and computed tomography (CT) to identify N2 and N3 disease in non small cell lung cancer (NSCLC) [abstract]. Presented at the 1998 American Society of Clinical Oncology Meeting; Abstract 1762.
)| false
KernstineKHStanfordWMullanBF. PET, CT, and MRI with combidex for mediastinal staging in non-small cell lung carcinoma. Ann Thorac Surg1999;68:1022–1028.
KernstineKHStanfordWMullanBF. PET, CT, and MRI with combidex for mediastinal staging in non-small cell lung carcinoma. Ann Thorac Surg1999;68:1022–1028.
)| false
DeLeyn PStroobantsSDe WeverW. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 non-small-cell lung cancer: a Leuven Lung Cancer Group Study. J Clin Oncol2006;24:3333–3339.
DeLeyn PStroobantsSDe WeverW. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 non-small-cell lung cancer: a Leuven Lung Cancer Group Study. J Clin Oncol2006;24:3333–3339.
)| false
PietermanRMvan PuttenJWMeuzelaarJJ. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med2000;343:254–261.
PietermanRMvan PuttenJWMeuzelaarJJ. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med2000;343:254–261.
)| false
ManentePVicarioGPiazzaF. Does PET/CT modify the therapeutic approach in medical oncology [abstract]?J Clin Oncol2008;26(Suppl 1):Abstract 17525.
ManentePVicarioGPiazzaF. Does PET/CT modify the therapeutic approach in medical oncology [abstract]?J Clin Oncol2008;26(Suppl 1):Abstract 17525.
)| false
DeWever WStroobantsSCoolenJVerschakelenJA. Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration. Eur Respir J2009;33:201–212.
DeWever WStroobantsSCoolenJVerschakelenJA. Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration. Eur Respir J2009;33:201–212.
)| false
VilmannPKrasnikMLarsenSS. Transesophageal endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) and endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) biopsy: a combined approach in the evaluation of mediastinal lesions. Endoscopy2005;37:833–839.
VilmannPKrasnikMLarsenSS. Transesophageal endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) and endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) biopsy: a combined approach in the evaluation of mediastinal lesions. Endoscopy2005;37:833–839.
)| false
YasufukuKNakajimaTMotooriK. Comparison of endobronchial ultrasound, positron emission tomography, and CT for lymph node staging of lung cancer. Chest2006;130:710–718.
YasufukuKNakajimaTMotooriK. Comparison of endobronchial ultrasound, positron emission tomography, and CT for lymph node staging of lung cancer. Chest2006;130:710–718.
)| false
KomakiRMountainCFHolbertJM. Superior sulcus tumors: treatment selection and results for 85 patients without metastasis (Mo) at presentation. Int J Radiat Oncol Biol Phys1990;19:31–36.
KomakiRMountainCFHolbertJM. Superior sulcus tumors: treatment selection and results for 85 patients without metastasis (Mo) at presentation. Int J Radiat Oncol Biol Phys1990;19:31–36.
)| false
RuschVWKrautMJCrowleyJ. Induction chemoradiotherapy and surgical resection for non-small cell lung carcinomas of the superior sulcus (pancoast tumors): mature results of Southwest Oncology Group trial 9416 (Intergroup trial 0160). Proc Am Soc Clin Oncol2003;22:Abstract 2548.
RuschVWKrautMJCrowleyJ. Induction chemoradiotherapy and surgical resection for non-small cell lung carcinomas of the superior sulcus (pancoast tumors): mature results of Southwest Oncology Group trial 9416 (Intergroup trial 0160). Proc Am Soc Clin Oncol2003;22:Abstract 2548.
)| false
BarnesJBJohnsonSBDahiyaRS. Concomitant weekly cisplatin and thoracic radiotherapy for Pancoast tumors of the lung: pilot experience of the San Antonio Cancer Institute. Am J Clin Oncol2002;25:90–92.
BarnesJBJohnsonSBDahiyaRS. Concomitant weekly cisplatin and thoracic radiotherapy for Pancoast tumors of the lung: pilot experience of the San Antonio Cancer Institute. Am J Clin Oncol2002;25:90–92.
)| false
RuschVWGirouxDJKrautMJ. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: initial results of Southwest Oncology Group trial 9416 (Intergroup trial 0160). J Thorac Cardiovasc Surg2001;121:472–483.
RuschVWGirouxDJKrautMJ. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: initial results of Southwest Oncology Group trial 9416 (Intergroup trial 0160). J Thorac Cardiovasc Surg2001;121:472–483.
)| false
van MeerbeeckJPKramerGWVan SchilPE. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst2007;99:442–450.
van MeerbeeckJPKramerGWVan SchilPE. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst2007;99:442–450.
)| false
OliaroAFilossoPLCavalloA. The significance of intrapulmonary metastasis in non-small cell lung cancer: upstaging or downstaging? A re-appraisal for the next TNM staging system. Eur J Cardiothorac Surg2008;34:438–443.
OliaroAFilossoPLCavalloA. The significance of intrapulmonary metastasis in non-small cell lung cancer: upstaging or downstaging? A re-appraisal for the next TNM staging system. Eur J Cardiothorac Surg2008;34:438–443.
)| false
PearsonFGDeLarueNCIlvesR. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg1982;83:1–11.
PearsonFGDeLarueNCIlvesR. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg1982;83:1–11.
)| false
RiceTW. Thoracoscopy in the staging of thoracic malignancies. In: Kaiser LR Daniel TM eds eds. Thoracoscopic Surgery. Philadelphia: Lippincott Williams 8 Wilkins; 1993:153–162.
RiceTW. Thoracoscopy in the staging of thoracic malignancies. In: Kaiser LR, Daniel TM, eds, eds. Thoracoscopic Surgery. Philadelphia: Lippincott Williams 8 Wilkins; 1993:153–162.
)| false
BurtMWronskiMArbitEGalicichJH. Resection of brain metastases from non-small-cell lung carcinoma. Results of therapy. Memorial Sloan-Kettering Cancer Center Thoracic Surgical Staff. J Thorac Cardiovasc Surg1992;103:399–410.
BurtMWronskiMArbitEGalicichJH. Resection of brain metastases from non-small-cell lung carcinoma. Results of therapy. Memorial Sloan-Kettering Cancer Center Thoracic Surgical Staff. J Thorac Cardiovasc Surg1992;103:399–410.
)| false
AlexanderE IIIMoriartyTMDavisRB. Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst1995;87:34–40.
AlexanderE IIIMoriartyTMDavisRB. Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst1995;87:34–40.
)| false
BurkesRLGinsbergRJShepherdFA. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto phase II trial. J Clin Oncol1992;10:580–586.
BurkesRLGinsbergRJShepherdFA. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto phase II trial. J Clin Oncol1992;10:580–586.
)| false
RuschVWAlbainKSCrowleyJJ. Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial. J Thorac Cardiovasc Surg1993;105:97–104; discussion 104–106.
RuschVWAlbainKSCrowleyJJ. Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial. J Thorac Cardiovasc Surg1993;105:97–104; discussion 104–106.
)| false
RosellRGomez-CodinaJCampsC. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med1994;330:153–158.
RosellRGomez-CodinaJCampsC. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med1994;330:153–158.
)| false
RothJAFossellaFKomakiR. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst1994;86:673–680.
RothJAFossellaFKomakiR. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst1994;86:673–680.
)| false
PistersKVallieresEBunnP. S9900: a phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): preliminary results [abstract]. J Clin Oncol2005;23(Suppl 1):Abstract LBA7012.
PistersKVallieresEBunnP. S9900: a phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): preliminary results [abstract]. J Clin Oncol2005;23(Suppl 1):Abstract LBA7012.
)| false
PistersKVallieresEBunnPAJr. S9900: surgery alone or surgery plus induction (ind) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): follow-up on a phase III trial [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 7520.
PistersKVallieresEBunnPAJr. S9900: surgery alone or surgery plus induction (ind) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): follow-up on a phase III trial [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 7520.
)| false
Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials.PORT Meta-analysis Trialists Group. Lancet1998;352:257–263.
Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials.PORT Meta-analysis Trialists Group. Lancet1998;352:257–263.
)| false
LallyBEZeltermanDColasantoJM. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol2006;24:2998–3006.
LallyBEZeltermanDColasantoJM. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol2006;24:2998–3006.
)| false
RosenLSGordonDTchekmedyianNS. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer2004;100:2613–2621.
RosenLSGordonDTchekmedyianNS. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer2004;100:2613–2621.
)| false
SocinskiMALangerCJHuangJE. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol2009;27:5255–5261.
SocinskiMALangerCJHuangJE. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol2009;27:5255–5261.
)| false
JohnsonDHFehrenbacherLNovotnyWF. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol2004;22:2184–2191.
JohnsonDHFehrenbacherLNovotnyWF. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol2004;22:2184–2191.
)| false
MezgerJvon PawelJReckM. Bevacizumab (Bv) single-agent maintenance following Bv-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): results from an exploratory analysis of the AVAiL study [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract e19001.
MezgerJvon PawelJReckM. Bevacizumab (Bv) single-agent maintenance following Bv-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): results from an exploratory analysis of the AVAiL study [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract e19001.
)| false
ReckMvon PawelJZatloukalP. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol2009;27:1227–1234.
ReckMvon PawelJZatloukalP. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol2009;27:1227–1234.
)| false
SocinskiMASchellMJPetermanA. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol2002;20:1335–1343.
SocinskiMASchellMJPetermanA. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol2002;20:1335–1343.
)| false
RielyGJKrisMGZhaoB. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res2007;13:5150–5155.
RielyGJKrisMGZhaoB. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res2007;13:5150–5155.
)| false
von MinckwitzGdu BoisASchmidtM. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol2009;27:1999–2006.
von MinckwitzGdu BoisASchmidtM. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol2009;27:1999–2006.
)| false
GazdarAF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene2009;28(Suppl 1):S24–31.
GazdarAF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene2009;28(Suppl 1):S24–31.
)| false
FossellaFVDeVoreRKerrRN. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol2000;18:2354–2362.
FossellaFVDeVoreRKerrRN. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol2000;18:2354–2362.
)| false
ShepherdFADanceyJRamlauR. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol2000;18:2095–2103.
ShepherdFADanceyJRamlauR. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol2000;18:2095–2103.
)| false
HannaNShepherdFAFossellaFV. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol2004;22:1589–1597.
HannaNShepherdFAFossellaFV. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol2004;22:1589–1597.
)| false
DemarinisFPaulSHannaN. Survival update for the phase III study of pemetrexed vs docetaxel in non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol2006;24(Suppl 1):Abstract 7133.
DemarinisFPaulSHannaN. Survival update for the phase III study of pemetrexed vs docetaxel in non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol2006;24(Suppl 1):Abstract 7133.
)| false
RamlauRGervaisRKrzakowskiM. Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. J Clin Oncol2006;24:2800–2807.
RamlauRGervaisRKrzakowskiM. Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. J Clin Oncol2006;24:2800–2807.
)| false
